Granted Patent
B2
US 12,233,412 · App. 18/066,803 · Granted Feb 25, 2025
Disposable fluidic cartridge and components
Inventors:
Robert Turner (San Diego, CA); James Madsen (San Diego, CA); Kai Yang (San Diego, CA); Juan Pablo Hinestrosa Salazar (San Diego, CA); Rajaram Krishnan (San Diego, CA); Pedro David Simon Herrera (San Diego, CA)
Assignee:
Xzom, Inc.
B01L3/502715B01L3/5027B01L2200/0684B01L2200/0689B01L2200/16B01L2300/023B01L2300/027B01L2300/041B01L2300/0645B01L2300/0654B01L2300/0681B01L2300/0861B01L2300/165B01L2300/168B01L2400/0424B01L2400/0487B01L2400/0638B01L2400/0694
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are cartridge components, cartridges, systems, and methods for isolating analytes from biological samples. In various aspects, the cartridge components, cartridges, systems, and methods may allow for a rapid procedure that requires a minimal amount of material from complex fluids.
Claims (24)
1. A compact device for isolating nanoscale analytes in a sample, the compact device comprising:
(a) a housing ( 101 ) comprising an optical pathway ( 106 ), wherein the housing is configured to receive a fluidic cartridge ( 104 ) comprising:
(i) a fluid moving mechanism ( 213 ), wherein the fluid moving mechanism draws fluid through the fluidic cartridge; and
(ii) a flowcell ( 209 ); and
(b) a camera ( 120 ) configured to capture a signal generated in the flowcell by the isolated nanoscale analytes,
wherein the fluidic cartridge comprises an electronic chip comprising a plurality of alternating current (AC) electrodes configured to capture the nanoscale analytes, wherein the optical pathway and the fluidic cartridge are optically transparent, and wherein the signal is indicative of the presence or absence of disease.
2. The compact device of claim 1 , wherein the signal comprises a fluorescent signal.
3. The compact device of claim 1 , wherein the optical pathway comprises a microscope objective or an endoscope objective.
4. The compact device of claim 1 , further comprising a portable computing device ( 103 ) configured to process the signal captured by the camera.
5. The compact device of claim 4 , wherein the camera is on the portable computing device.
6. The compact device of claim 1 , further comprising a light configured to provide optical excitation of the isolated nanoscale analytes.
7. The compact device of claim 1 , wherein the optical pathway comprises an optical detector.
8. The compact device of claim 1 , wherein the optical detector comprises a charged coupled device or a photomultiplier tube.
9. The compact device of claim 1 , wherein the optical pathway comprises an optical filter.
10. The compact device of claim 1 , wherein the AC electrodes are configured to be selectively energized to establish dielectrophoretic (DEP) high field and DEP low field regions.
11. The compact device of claim 1 , wherein the fluidic cartridge further comprises a plurality of alternating current (AC) electrodes configured to be selectively energized to establish dielectrophoretic (DEP) high field and DEP low field regions, wherein AC electrokinetic effects separate nanoscale analytes from larger molecular entities.
12. The compact device of claim 1 , wherein the fluidic cartridge is inserted into a fluidic cartridge slot of the compact device.
13. The compact device of claim 1 , wherein the compact device is connected to the portable computing device via a charging port, a USB port, or a headphone port of the portable computing device.
14. The compact device of claim 1 , wherein the compact device comprises a communication interface operating on 3G communication protocols, 4G communication protocols, IEEE 802.11 standards, BlueTooth protocols, short range RF communications, satellite communications, visible light communications, infrared communications, or combinations thereof.
15. The compact device of claim 1 , wherein the compact device comprises a wired communication interface comprising USB, RJ45, serial port, parallel port, or combinations thereof.
16. The compact device of claim 1 , wherein the compact device comprises a flat top plate, such that the portable computing device rests on the flat top plate of the compact device.
17. The compact device of claim 1 , wherein the portable computing device is a smart phone or a tablet computer.
18. The compact device of claim 1 , wherein the nanoscale analytes comprise nucleic acid.
19. The compact device of claim 1 , wherein the disease comprises cardiovascular disease, neurodegenerative disease, diabetes, auto-immune disease, inflammatory disease, cancer, metabolic disease, prion disease, or pathogenic disease.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 24, 2025
From: BIOLOGICAL DYNAMICS, INC.
To: BIOLOGICAL LIQUIDATION, LLC
Reel/Frame 069994/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 24, 2025
From: BIOLOGICAL LIQUIDATION, LLC
To: JACOBS FAMILY TRUST
Reel/Frame 070000/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 24, 2025
From: JACOBS FAMILY TRUST
To: XZOM, INC.
Reel/Frame 070000/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 19, 2022
From: TURNER, ROBERT; MADSEN, JAMES; YANG, KAI; HINESTROSA SALAZAR, JUAN PABLO; KRISHNAN, RAJARAM; SIMON HERRERA, PEDRO DAVID
To: BIOLOGICAL DYNAMICS, INC.
Reel/Frame 062144/0197 →
Continuity (4)
Provisional Application
62313120
· Mar 24, 2016
References Cited (400)
US 5632957A
· Heller et al.
· 1997
[cited by applicant]
US 5958791A
· Roberts et al.
· 1999
[cited by applicant]
US 6149789A
· Benecke et al.
· 2000
[cited by applicant]
US 6203683B1
· Austin et al.
· 2001
[cited by applicant]
US 6280590B1
· Cheng et al.
· 2001
[cited by applicant]
US 6289590B1
· McDonald
· 2001
[cited by applicant]
US 6294063B1
· Becker et al.
· 2001
[cited by applicant]
US 6352838B1
· Krulevitch et al.
· 2002
[cited by applicant]
US 6403367B1
· Cheng et al.
· 2002
[cited by applicant]
US 6557575B1
· Gerhardt et al.
· 2003
[cited by applicant]
US 6749736B1
· Fuhr et al.
· 2004
[cited by applicant]
US 6824664B1
· Austin et al.
· 2004
[cited by applicant]
US 6887362B2
· Huang et al.
· 2005
[cited by applicant]
US 7081189B2
· Squires et al.
· 2006
[cited by applicant]
US 7105081B2
· Gascoyne et al.
· 2006
[cited by applicant]
US 7447922B1
· Asbury et al.
· 2008
[cited by applicant]
US 7709262B2
· Cantor et al.
· 2010
[cited by applicant]
US 8372657B2
· Reboud et al.
· 2013
[cited by applicant]
US 8425750B2
· Sugioka
· 2013
[cited by applicant]
US 8603791B2
· Krishnan et al.
· 2013
[cited by applicant]
US 8815554B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8815555B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8871481B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8877470B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8932447B2
· Heller et al.
· 2015
[cited by applicant]
US 8932815B2
· Krishnan et al.
· 2015
[cited by applicant]
US 8969059B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9005941B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9034578B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9034579B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9169521B1
· Rajagopal et al.
· 2015
[cited by applicant]
US 9206416B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9387489B2
· Charlot et al.
· 2016
[cited by applicant]
US 9499812B2
· Krishnan et al.
· 2016
[cited by applicant]
US 9682385B2
· Charlot et al.
· 2017
[cited by applicant]
US 9827565B2
· Krishnan et al.
· 2017
[cited by applicant]
US 9918702B2
· Tariyal et al.
· 2018
[cited by applicant]
US 20020036142A1
· Gascoyne et al.
· 2002
[cited by applicant]
US 20040011650A1
· Zenhausern et al.
· 2004
[cited by applicant]
US 20040011651A1
· Becker et al.
· 2004
[cited by applicant]
US 20040052689A1
· Yao
· 2004
[cited by applicant]
US 20040086872A1
· Childers et al.
· 2004
[cited by applicant]
US 20060096367A1
· Meyer et al.
· 2006
[cited by applicant]
US 20060102482A1
· Auerswald et al.
· 2006
[cited by applicant]
US 20070080062A1
· Harnett et al.
· 2007
[cited by applicant]
US 20070095669A1
· Lau et al.
· 2007
[cited by applicant]
US 20070131554A1
· Yu et al.
· 2007
[cited by applicant]
US 20070141605A1
· Vann et al.
· 2007
[cited by applicant]
US 20070152206A1
· Cho et al.
· 2007
[cited by applicant]
US 20070240495A1
· Hirahara
· 2007
[cited by applicant]
US 20070289341A1
· Hollenhorst et al.
· 2007
[cited by applicant]
US 20090061450A1
· Hunter
· 2009
[cited by applicant]
US 20090314644A1
· Golan et al.
· 2009
[cited by applicant]
US 20090325813A1
· Wang et al.
· 2009
[cited by applicant]
US 20100155246A1
· Schnelle et al.
· 2010
[cited by applicant]
US 20100211407A1
· Duke et al.
· 2010
[cited by applicant]
US 20110009724A1
· Hill et al.
· 2011
[cited by applicant]
US 20110020785A1
· Lowery, Jr. et al.
· 2011
[cited by applicant]
US 20110100820A1
· Bachmann et al.
· 2011
[cited by applicant]
US 20110108422A1
· Heller et al.
· 2011
[cited by applicant]
US 20110192726A1
· Chen et al.
· 2011
[cited by applicant]
US 20130052748A1
· Campbell et al.
· 2013
[cited by applicant]
US 20130274148A1
· Kain et al.
· 2013
[cited by applicant]
US 20140054172A1
· Jonsson et al.
· 2014
[cited by applicant]
US 20140170679A1
· Aitchison et al.
· 2014
[cited by applicant]
US 20140367260A1
· Dickerson et al.
· 2014
[cited by applicant]
US 20150136604A1
· Nielsen et al.
· 2015
[cited by applicant]
US 20150219618A1
· Krishnan et al.
· 2015
[cited by applicant]
US 20160232562A1
· Esayian et al.
· 2016
[cited by applicant]
US 20160327549A1
· Charlot et al.
· 2016
[cited by applicant]
US 20170370836A1
· Gerion et al.
· 2017
[cited by applicant]
US 20180274014A1
· Krishnan et al.
· 2018
[cited by applicant]
US 20210020275A1
· Krishnan et al.
· 2021
[cited by applicant]
US 20210214798A1
· Krishnan et al.
· 2021
[cited by applicant]
US 20230250536A1
· Harris et al.
· 2023
[cited by applicant]
US 20240069035A1
· Krishnan et al.
· 2024
[cited by applicant]
CA 2870160A1
· 2013
[cited by applicant]
CN 1337580A
· 2002
[cited by applicant]
CN 1348100A
· 2002
[cited by applicant]
CN 101208593A
· 2008
[cited by applicant]
CN 102320559A
· 2012
[cited by applicant]
EP 1775589A1
· 2007
[cited by applicant]
GB 2516666A
· 2015
[cited by applicant]
JP H0663360A
· 1994
[cited by applicant]
JP H11514087A
· 1999
[cited by applicant]
JP 2001500252A
· 2001
[cited by applicant]
JP 2002502047A
· 2002
[cited by applicant]
JP 2004532968A
· 2004
[cited by applicant]
JP 2005501251A
· 2005
[cited by applicant]
JP 2006135191A
· 2006
[cited by applicant]
JP 2008298575A
· 2008
[cited by applicant]
JP 2011516867A
· 2011
[cited by applicant]
JP 2011522219A
· 2011
[cited by applicant]
JP 2013536679A
· 2013
[cited by applicant]
JP 2013232627A
· 2013
[cited by applicant]
JP 2014521954A
· 2014
[cited by applicant]
JP 2017512483A
· 2017
[cited by applicant]
TW 201726540A
· 2017
[cited by applicant]
WO WO9804355A1
· 1998
[cited by applicant]
WO WO9938612A1
· 1999
[cited by applicant]
WO WO0196025A2
· 2001
[cited by applicant]
WO WO2005012872A2
· 2005
[cited by applicant]
WO WO2005031300A2
· 2005
[cited by applicant]
WO WO2005121767A1
· 2005
[cited by applicant]
WO WO2006018981A1
· 2006
[cited by applicant]
WO WO2006120656A1
· 2006
[cited by applicant]
WO WO2007106552A2
· 2007
[cited by applicant]
WO WO2007107910A1
· 2007
[cited by applicant]
WO WO2009146143A2
· 2009
[cited by applicant]
WO WO2012028746A1
· 2012
[cited by applicant]
WO WO2013060762A1
· 2013
[cited by applicant]
WO WO2014011740A1
· 2014
[cited by applicant]
WO WO2014015187A1
· 2014
[cited by applicant]
WO WO2014028222A1
· 2014
[cited by applicant]
WO WO2014207731A1
· 2014
[cited by applicant]
WO WO2015097858A1
· 2015
[cited by applicant]
WO WO2015148808A1
· 2015
[cited by applicant]
WO WO2015157217A1
· 2015
[cited by applicant]
WO WO2015196141A1
· 2015
[cited by applicant]
WO WO2016025698A1
· 2016
[cited by applicant]
WO WO2017125475A1
· 2017
[cited by applicant]
WO WO2017165852A1
· 2017
[cited by applicant]
WO WO2017181030A2
· 2017
[cited by applicant]
WO WO2018112265A1
· 2018
[cited by applicant]
WO WO2018208820A1
· 2018
[cited by applicant]
WO WO2019126388A1
· 2019
[cited by applicant]
WO WO2019126391A1
· 2019
[cited by applicant]
WO WO2019195196A1
· 2019
[cited by applicant]
WO WO2019200323A1
· 2019
[cited by applicant]
WO WO2022011313A1
· 2022
[cited by applicant]
WO WO2022155223A1
· 2022
[cited by applicant]
Ohwaki: Characterization of native oxide on aluminum by infrared spectroscopy. 54(1):31-36. doi: 10.2464/jilm.54.31 [with English Machine Translation] (2004).
[cited by applicant]
U.S. Appl. No. 16/955,732 Non-Final Office Action dated Mar. 23, 2023.
[cited by applicant]
U.S. Appl. No. 17/033,427 Final Office Action dated Apr. 21, 2023.
[cited by applicant]
Asbury et al. Trapping of DNA by dielectrophoresis. Electrophoresis 23:2658-2666 (2002).
[cited by applicant]
Asbury et al. Trapping of DNA in Nonuniform Oscillating Electric Fields. Biophys J. 74:1024-1030 (1998).
[cited by applicant]
Becker et al. Separation of Human Breast Cancer Cells From Blood by Differential Dielectric Affinity. Proceedings of the National Academy of Sciences 92:860-864 (1995).
[cited by applicant]
Becker et al. The removal of human leukemia cells from blood using interdigitated microelectrodes. J Phys. D: Appl. Phys. 27:2659-2662 (1994).
[cited by applicant]
Berg et al. Cellphone-Based Hand-Held Microplate Reader for Point-of-Care Testing of Enzyme-Linked Immunosorbent Assays. ACS Nano 9(8):7857-7866 (2015).
[cited by applicant]
Bettegowda et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 6:224 (2014).
[cited by applicant]
Board et al. DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer. Biomark Insights 2:307-319 (2007).
[cited by applicant]
Board et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann. N. Y. Acad. Sci. 1137:98-107 (Aug. 2008).
[cited by applicant]
Cairns. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann N Y Acad Sci. 1022:40-43 (Jun. 2004).
[cited by applicant]
Casciano et al. Circulating Tumor Nucleic Acids: Perspective in Breast Cancer. Breast Care 5:75-80 (2010).
[cited by applicant]
Catarino et al. Quantification of Free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 27(8):415-421 (Aug. 2008).
[cited by applicant]
Chan. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol. 12(6):489-496 (Dec. 2002).
[cited by applicant]
Chan et al. Nasopharyngeal carcinoma. Annals of Oncology 13:1007-1015 (2002).
[cited by applicant]
Chan et al. Persistent Aberrations in Circulating DNA Integrity after Radiotherapy Are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research 14(13):4141-4145 (2008).
[cited by applicant]
Chan et al. Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. Clinical Chemistry 54(9):1528-1536 (2008).
[cited by applicant]
Chan et al. Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer 6:259 (Oct. 31, 2006).
[cited by applicant]
Cheng et al. Isolation of Cultured Cervical Carcinoma Cells Mixed with Peripheral Blood Cells on a Bioelectronic Chip. Analytical Chemistry 70(11):2321-2326 (1998).
[cited by applicant]
Cheng et al. Preparation and Hybridization Analysis of DNA/A from
[cited by applicant]
Cheng et al. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Science 100(2):303-309 (Feb. 2009).
[cited by applicant]
Chuang et al. Detectable BRAF mutation n serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 32(2):229-234 (2010).
[cited by applicant]
Chun et al. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU International 98(3):544-548 (2006).
[cited by applicant]
Cohen, et al., Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science Feb. 23, 2018: vol. 359, Issue 6378, pp. 926-930. DOI: 10.1126/science.aar3247.
[cited by applicant]
Combaret et al. Circulating MYCN DNA as a Tumor-specific Marker in Neuroblastoma Patients. Cancer Research 62:3646-3648 (Jul. 1, 2002).
[cited by applicant]
Cortese et al. Epigenetic markers of prostate cancer in plasma circulating DNA. Human Molecular Genetics 21:3619-3631 (2012).
[cited by applicant]
Da Silva et al. Circulating cell-free DNA in serum as a biomarker of colorectal cancer. Journal of Clinical Pathology 66(9):775-778 (Sep. 2013).
[cited by applicant]
Daniotti et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int. J. Cancer 120:2439-2444 (Jun. 1, 2007).
[cited by applicant]
Dawson et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-1209 (2013).
[cited by applicant]
De Maio et al. Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. World Journal of Gastroenterology 20(4):957-967 (Jan. 28, 2014).
[cited by applicant]
Deglado. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumor Biol. 34(2):983-986 (Apr. 2013).
[cited by applicant]
Deligezer et al. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann N Y Acad Sci. 1137:175-179 (Aug. 2008).
[cited by applicant]
Devos et al. Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer. Clinical Chemistry 55(7):1337-1346 (Jul. 2009).
[cited by applicant]
Dobrzycka. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Annals of Oncology 22(5):1133-1140 (May 2011).
[cited by applicant]
Dobrzycka. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. 127(3):612-621 (Aug. 1, 2010).
[cited by applicant]
Dvorak: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 20(21):4368-4380 doi:10.1200/JCO.2002.10…
[cited by applicant]
El Tarhouny et al. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine 44(1):65-69 (Oct. 2008).
[cited by applicant]
Ellinger et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J. Urol. 181(1):363-371 (Jan. 2009).
[cited by applicant]
Ellinger et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol. 182(1):324-329 (Jul. 2009).
[cited by applicant]
Ellinger et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int. J. Cancer 122(1):138-143 (Jan. 1, 2008).
[cited by applicant]
Elshimali et al. The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients. Int. J. Mol. Sci. 14(9):18925-18958 (Sep. 13, 2013).
[cited by applicant]
Fuhr et al. Cell manipulation and cultivation under a.c. electric field influence in highly conductive culture media. Biochimica et Biophysica Acta 1201:353-360 (1994).
[cited by applicant]
Gahan et al. Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer. EPMA Journal 1(3):503-512 (Sep. 2010).
[cited by applicant]
Ganepola et al. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World Journal of Gastrointestinal Oncology 6(4):83-97 (Apr. 15, 2014).
[cited by applicant]
Gao et al.: Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med. 48(11):1651-1656 doi:10.1515/CCLM.2010.311. (2010).
[cited by applicant]
Gautschi et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 22(20):4157-4164 (2004).
[cited by applicant]
Goessl et al. DNA Alterations in Body Fluids as Molecular Tumor Markers for Urological Malignancies. European Urology 41(6):668-676 (Jun. 2002).
[cited by applicant]
Goodard et al. Handbook of Nanoscience. 2nd edition.Ch 16, p. 5-8 (2007).
[cited by applicant]
Gornik et al. Free serum DNA is an early predictor of severity of acute pancreatitis. Clin Biochem. 42(1-2):38-43 (Jan. 2009).
[cited by applicant]
Green et al. Ac electrokinetics: a survey of sub-micrometre particle dynamics. J. Phys. D: Appl. Phys. 33:632-641 (2000).
[cited by applicant]
Guan et al. Analysis of circulating DNA level in the plasma of cervical cancer patients. Nan fang Yi Ke Da Xue Xue Bao 28(9):1663-1667 (Aug. 2008) (English Abstract).
[cited by applicant]
Haeberle et al. Centrifugal extraction of plasma from whole blood on a rotating disk. Lab Chip 6(6):776-781 (2006).
[cited by applicant]
Hashad et al. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 26(6):467-472 (Nov. 2012).
[cited by applicant]
Higgins et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. PNAS USA 109(45):E3128-3135 (Nov. 6, 2012).
[cited by applicant]
Higuchi. Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. Biochem Pharacol. 66:1527-1535(2003).
[cited by applicant]
Higuchi et al. Appearance of 1-2 Mbp giant DNA fragments as an early common response leading to cell death induced by various substances that cause oxidative stress. Free Radical Biology & Medicine 23:90-99 (1997).
[cited by applicant]
Hinestrosa et al.: Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform. Front Bioeng Biotechnol. 8(581157):1-13 doi…
[cited by applicant]
Hoffmann et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol. 135(89):1231-1237 (Sep. 2009).
[cited by applicant]
Hoffmann et al. Universal protocol for grafting PCR primers onto various lab-on-a-chip substrates for solid-phase PCR. RSC Advances 2:3885-3889 (2012).
[cited by applicant]
Hohaus et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Annals of Oncology 20(8):1408-1413 (2009).
[cited by applicant]
Holdhoff et al. Blood-based biomarkers for malignant gliomas. J Neurooncol 113:345-352 (2013).
[cited by applicant]
Holzel et al. Trapping Single Molecules by Dielectrophoresis. Phys. Rev. Left. 95:128102 (2005).
[cited by applicant]
Hoshino et al.: Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell 182(4):1044-1061.E18. doi:10.1016/j.cell.2020.07.009 (2020).
[cited by applicant]
Hoshino et al.: Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329-335 doi:10.1038/nature15756 (2015).
[cited by applicant]
Hosny et al. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett. 264(2):201-208 (Jun. 18, 2008).
[cited by applicant]
Huang et al. Dielectrophoretic Cell Separation and Gene Expression Profiling on Microelectronic Chip Arrays. Analytical Chem. 74:3362-3371 (2002).
[cited by applicant]
Huang et al. Electric Manipulation of Bioparticles and Macromolecules on Microfabricated Electrodes. Analytical Chemistry (73):1549-1559 (2001).
[cited by applicant]
Huang et al. Functionalization of Surfaces by Water-Accelerated Atom-Transfer Radical Polymerization of Hydroxyethyl Methacrylate and Subsequent Derivatization. Macromolecules 35:1175-1179 (2002).
[cited by applicant]
Hughes. Chapter 16: Nanoparticle Manipulation by Electrostatic Forces. Handbook of Nanoscience, Engineering and Technology 2nd Ed., WA Goddard III, DW Brenner, S. Lyshenski & G. Iafrate (eds.) (CRC Press 2007), pp. 16-1…
[cited by applicant]
Hughes et al. Dielectrophoretic Characterization and Separation of Antibody-Coated Submicrometer Latex Spheres. Anal Chem 71:3441-3445 (1999).
[cited by applicant]
Hughes et al. Dielectrophoretic Manipulation and Characterization of Herpes Simplex Virus-1 Capsids. Eur Biophys J 30:268-272 (2001).
[cited by applicant]
Hughes. Strategies for Dielectrophoretic Separation in Laboratory-on-a-chip Systems. Electrophoresis 23:2569-2582 (2002).
[cited by applicant]
Iida et al. Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncology Reports 20(4):761-765 (Oct. 2008).
[cited by applicant]
Iizuka et al. Elevated Levels of Circulating Cell-free DNA in the Blood of Patients with Hepatitis C Virus-associated Hepatocellular Carcinoma. Anticancer Research 26(6C):4713-4720 (2006).
[cited by applicant]
Jiang et al. Dynamic monitoring of plasma circulating DNA in patients with acute myeloid leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20(1):53-56 (Feb. 2012) (Abstract).
[cited by applicant]
Jiang et al. Increased plasma DNA integrity index in head and neck cancer patients. Int. J. Cancer 119(11):2673-2676 (Dec. 2006).
[cited by applicant]
Jin et al. Circulating DNA-Important Biomarker of Cancer. Journal of Molecular Biomarkers & Diagnosis S2 (2012) (7 pgs.).
[cited by applicant]
Juppner. Functional properties of the PTH/PTHrP receptor. Bone. Aug. 1995; 17(2):Supplement 39S-42S.
[cited by applicant]
Kakimoto et al. Microsatellite analysis of serum DNA in patients with oral squamous cell carcinoma. Oncology Reports 20(5):1195-1200 (Nov. 2008).
[cited by applicant]
Kjaergaard et al.: The use of the soluble adhesion molecules sE-selectin, SICAM-1, SVCAM-1, sPECAM-1 and their ligands CD11a and CD49d as diagnostic and prognostic biomarkers in septic and critically ill non-septic ICU …
[cited by applicant]
Kolesnikova et al. Circulating DNA in the blood of gastric cancer patients. Ann N Y Acad Sci. 1137:226-231 (Aug. 2008).
[cited by applicant]
Krishnan et al. Alternating current electrokinetic separation and detection of DNA nanoparticles in high-conductance solutions. Electrophoresis 29(9):1765-1774 (2008).
[cited by applicant]
Krishnan et al. An AC electrokinetic method for enhanced detection of DNA nanoparticles. J. Biophotonics 2(4):253-261 (2009).
[cited by applicant]
Krishnan et al. Interaction of nanoparticles at the DEP microelectrode interface under high conductance conditions. Electrochem. Comm. 11(8):1661-1666 (2009).
[cited by applicant]
Kuhlmann et al. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer 12:3525 (Jul. 31, 2012).
[cited by applicant]
Lavon et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology 12(2):173-180 (2010).
[cited by applicant]
Lee et al. A micro cell lysis device. Sensors and Actuators A: Physical. 73(1-2):74-79 (1999).
[cited by applicant]
Lee et al. Methylation of TMEFF2 Gene in Tissue and Serum DNA from Patients with Non-Small Cell Lung Cancer. Molecules and Cells 34(2):171-176 (Aug. 31, 2012).
[cited by applicant]
Lennartsson et al.: Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 92(4):1619-1649 doi:10.1152/physrev.00046.2011 (2012).
[cited by applicant]
Lida et al. Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncol Rep. 20(4):761-5 (2008).
[cited by applicant]
Liggett et al. Differential Methylation of Cell-Free Circulating DNA Among Patients With Pancreatic Cancer Versus Chronic Pancreatitis. Cancer 116(7):1674-1680 (Apr. 1, 2010).
[cited by applicant]
Liggett et al. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int. J. Cancer 128(2):492-499 (Jan. 15, 2011).
[cited by applicant]
Liu et al. Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA. Annals of Oncology 31(6):745-759 (2020).
[cited by applicant]
Lo Nigro et al. Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. Journal of Investigative Dermatology 133(5):1278-1285 (May 2013).
[cited by applicant]
Lofton-Day et al. DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening. Clinical Chemistry 54(2):414-423 (Feb. 2008).
[cited by applicant]
Lu et al.: Abstract: AC electrokinetic isolation of cell free high molecular weight DNA (CF-HMW DNA) from serum. American Association for Cancer Research Publication 72(8):1704 URL: https://doi.org/10.1158/1538-7445.AM2…
[cited by applicant]
Ma et al. Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients. Zhonghua Bing Li Xue Za Zhi. 34(12):785-787 (Dec. 2005) (Abstract).
[cited by applicant]
Ma et al. Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection. International Journal of Molecular Sciences 14(5):10307-10331 (May 16, 2013).
[cited by applicant]
Majchrzak et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J. Appl. Genetics 54:335-344 (2013).
[cited by applicant]
Melnikov et al. Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 99(2):119-122 (Feb. 2009).
[cited by applicant]
Menachery et al. Controlling cell destruction using dielectrophoretic forces. IEE Proc.-Nanobiotechnol. 152(4):145-149 (2005).
[cited by applicant]
Mirza et al. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 19(9):3107-3115 (Sep. 2012).
[cited by applicant]
Misale et al. Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer. Nature 486(7404):532-536 (Jun. 28, 2012).
[cited by applicant]
Misawa et al. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. British Journal of Cancer 100:399-404 (2009).
[cited by applicant]
Moasser: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469-6487 doi:10.1038/sj.onc.1210477 (2007).
[cited by applicant]
Moreira, et al. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. Clin Chem. Nov. 2009;55(11):1958-66. doi: 10.1373/clinchem.2009.129072. Epub Sep. 3, 2009.
[cited by applicant]
Morgan et al. Separation of Sub micron Bioparticles by Dielectrophoresis Biophysical Journal. 77:516-525 (1999).
[cited by applicant]
Mouliere et al. Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Translational Oncology 6(3):319-328 (Jun. 2013).
[cited by applicant]
Mouliere et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6(9):e23418 (2011).
[cited by applicant]
Muller et al. DNA Methylation in Serum of Breast Cancer Patients: An Independent Prognostic Marker. Cancer Research 63(22):7641-7645 (Nov. 15, 2003).
[cited by applicant]
Muller et al. Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements. Clinical Chemistry 54(4):688-696 (Apr. 2008).
[cited by applicant]
Nakagawa et al. Fabrication of amino Silane-Coated Microchip for DNA extraction from Whole Blood. Journal of Biotechnology 116(2):105-111 (2005).
[cited by applicant]
Nakamoto et al. Detection of Microsatellite Alterations in Plasma DNA of Malignant Mucosal Melanoma Using Whole Genome Amplification. Bull Tokyo Dent. Coll. 49(2):77-87 (May 2008).
[cited by applicant]
Nakamura et al. Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA. Journal of Thoracic Oncology 7(9):1369-1381 (Sep. 2012).
[cited by applicant]
Nakayama et al. A Highly Sensitive Method for the Detection of p16 Methylation in the Serum of Colorectal Cancer Patients. Anticancer Research 27(3B):1459-1464 (2007).
[cited by applicant]
Niland et al.: Neuropilins in the Context of Tumor Vasculature. Int J Mol Sci. 20(3):639, pp. 1-44 doi:10.3390/ijms20030639 (2019).
[cited by applicant]
Page et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. British Journal of Cancer 104:1342-1348 (2011).
[cited by applicant]
Pang et al. Microsatellite alterations of circulating DNA in the plasma of patients with hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 86(24):1662-1665 (Jun. 27, 2006) (Abstract).
[cited by applicant]
Papadopoulou et al. Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer, Ann. NY, Acad. Sci. 1075:235-243 (2006).
[cited by applicant]
PCT/US2009/039565 International Preliminary Report on Patentability and Written Opinion dated Oct. 5, 2010.
[cited by applicant]
PCT/US2009/039565 International Search Report dated Dec. 23, 2009.
[cited by applicant]
PCT/US2013/036845 International Search Report and Written Opinion dated Aug. 6, 2013.
[cited by applicant]
PCT/US2013/051158 International Search Report and Written Opinion dated Nov. 14, 2013.
[cited by applicant]
PCT/US2015/024624 International Search Report and Written Opinion dated Aug. 21, 2015.
[cited by applicant]
PCT/US2015/036789 International Search Report and Written Opinion dated Sep. 29, 2015.
[cited by applicant]
PCT/US2017/024149 International Search Report and Written Opinion dated Jul. 18, 2017.
[cited by applicant]
PCT/US2017/024149 Invitation to Pay Additional Fees dated May 15, 2017.
[cited by applicant]
PCT/US2018/031652 International Search Report and Written Opinion dated Jul. 31, 2018.
[cited by applicant]
PCT/US2018/066602 International Search Report and Written Opinion dated Apr. 4, 2019.
[cited by applicant]
PCT/US2018/066605 International Search Report and Written Opinion dated Mar. 25, 2019.
[cited by applicant]
PCT/US2019/025242 International Search Report and Written Opinion dated Jun. 11, 2019.
[cited by applicant]
PCT/US2021/041177 International Search Report and Written Opinion dated Oct. 19, 2021.
[cited by applicant]
PCT/US2022/012149 International Search Report and Written Opinion dated Apr. 11, 2022.
[cited by applicant]
Persat, et al., Purification of Nucleic Acids from Whole Blood Using Isotachophoresis, Analytical Chemistry, 81.22 (Nov. 15, 2009): 9507-9511, supporting materials.
[cited by applicant]
Pethig. Dielectrophoresis: Using Inhomogenous AC Electrical Fields to Separate and Manipulate Cells, CRC Critical Reviews in Biotechnology, CRC Press, Boca Raton, FL, US. 16(4):331-348 (Jan. 1, 1996).
[cited by applicant]
Ponomaryova et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer. 81(3):397-403 (Sep. 2013).
[cited by applicant]
Quesada-Gonzalez et al. Mobile phone-based biosensing: An emerging “diagnostic and communication” technology. Biosensors And Bioelectronics 92:549-562 (2016).
[cited by applicant]
Ramos et al. Ac electrokinetics: a review of forces in microelectrode structures. J Phys. D: Appl. Phys. 31:2338-2353 (1998).
[cited by applicant]
Ren et al. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World Journal of Gastroenterology 12(24):3911-3914 (Jun. 28, 2006).
[cited by applicant]
Ross et al.: Binding affinity of surface functionalized gold nanoparticles to hydroxyapatite. J Biomed Mater Res A. 99(1):58-66 (2011).
[cited by applicant]
Sai et al. Quantification of Plasma Cell-free DNA in Patients with Gastric Cancer. Anticancer Research 27(4C):2747-2752 (2007).
[cited by applicant]
Sakakura et al. Quantitative Analysis of Tumor-derived Methylated RUNX3 Sequences in the Serum of Gastric Cancer Patients. Anticancer Research 29:2619-2626 (2009).
[cited by applicant]
Salkeni et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J. Neurooncol. 115(1):27-35 (Oct. 2013).
[cited by applicant]
Sawabu et al. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 28(3):263-267 (Apr. 2004).
[cited by applicant]
Schwarzenbach. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci. 1137:190-196 (Aug. 2008).
[cited by applicant]
Schwarzenbach. Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression. Clinical Cancer Research 18:5719-5730 (Sep. 25, 2012).
[cited by applicant]
Sharma et al. DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol. 33(6):1837-1843 (Dec. 2012).
[cited by applicant]
Shaw et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Research 22(2):220-231 (Feb. 2012).
[cited by applicant]
Sonnenberg et al.: Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 35(12-13):1828-1836 (2014).
[cited by applicant]
Sonnenberg et al. Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. Electrophoresis 34(7):1076-1084 (2013).
[cited by applicant]
Sonnenberg et al. Dielectrophoretic Isolation of DNA and Nanoparticles from Blood. Electrophoresis 33(16):2482-2490 (2012).
[cited by applicant]
Sorenson. Detection of Mutated KRAS2 Sequences as Tumor Markers in Plasma/Serum of Patients with Gastrointestinal Cancer. Clin Cancer Res 6:2129-2137 (2000).
[cited by applicant]
Sosnowski et al. Rapid determination of single base mismatch mutations in DNA hybrids by direct electric field control. PNAS USA 94:1119-1123 (Feb. 1997).
[cited by applicant]
Stephens et al. The dielectrophoresis enrichment of CD34+ cells from peripheral blood stern cell harvests. Bone Marrow Transplant. 18:777-782 (1996).
[cited by applicant]
Stroun et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23:707-712 (1987).
[cited by applicant]
Swanson. A fully multiplexed CMOS biochip for DNA analysis. Sensors and Actuators B 64:22-30 (Jun. 2000).
[cited by applicant]
Tamkovich et al. Cell-surface-bound circulating DNA as a prognostic factor in lung cancer. Ann N Y Acad Sci. 1137:214-217 (Aug. 2008).
[cited by applicant]
Tanaka et al. Role of circulating free alu DNA in endometrial cancer. Int J Gynecol Cancer 22(1):82-86 (Jan. 2012).
[cited by applicant]
Tangkijvanich et al. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta. 379(1-2):127-133 (Apr. 2007).
[cited by applicant]
Tani et al. An early detection of recurrence using reverse transcriptase-polymerase chain reaction (RT-PCP) and methylation-specific polymerase chain reaction (MSP) from peripheral blood in patients after gastrectomy. G…
[cited by applicant]
Tomita et al. Quantification of Circulating Plasma DNA Fragments as Tumor Markers in Patients with Esophageal Cancer, Anticancer Research 27(4C):2737-2742 (2007).
[cited by applicant]
Toner et al. Blood-on-a-chip. Annual Review of Biomedical Engineering 7:77-103 (2005).
[cited by applicant]
Tong et al. Diagnostic developments involving cell-free (circulating) nucleic acids. Clinica Chimica Acta. 363:187-96 (2006).
[cited by applicant]
Toth et al. Free circulating DNA based colorectal cancer screening from peripheral blood: the possibility of the methylated septin 9 gene marker. Orv. Hetil. 150(21):969-977(May 24, 2009) (English Abstract).
[cited by applicant]
Trevisiol et al. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int J Biol Markers. 21(4):223-228 (Oct.-Dec. 2006).
[cited by applicant]
Turner et al.: Cancer Detection at your Fingertips: Smartphone-Enabled DNA Testing. Annu Int Conf IEEE Eng Med Biol Soc. 2018:5418-5421 doi: 10.1109/EMBC.2018.8513553 (2018).
[cited by applicant]
Tuukanen et al. Carbon nanotubes as electrodes for dielectrophoresis of DNA. Nano Letters. 6:1339-1343 (2006).
[cited by applicant]
Umetani et al. Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats. Clinical Chemistry 52(6):1062-1069 (Jun. 2006).
[cited by applicant]
Umetani et al. Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum. Journal of Clinical Oncology 24(26):4270-4276 (Sep. 10, 2006).
[cited by applicant]
U.S. Appl. No. 16/355,462 Final Office Action dated Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 16/955,707 Non-Final Office Action dated Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 16/955,707 Non-Final Office Action mailed Jan. 31, 2023, restarting response period for Non-Final Office Action mailed on Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 16/955,732 Final Office Action dated Apr. 29, 2022.
[cited by applicant]
U.S. Appl. No. 16/955,732 Non-Final Office Action dated Nov. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/033,427 Non-Final Office Action dated Oct. 6, 2022.
[cited by applicant]
U.S. Appl. No. 17/045,146 Non-Final Office Action dated Mar. 6, 2023.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Apr. 27, 2015.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Aug. 12, 2015.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Dec. 11, 2012.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Jul. 18, 2013.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Mar. 17, 2017.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Oct. 31, 2012.
[cited by applicant]
U.S. Appl. No. 12/936,147 Office Action dated Sep. 22, 2016.
[cited by applicant]
U.S. Appl. No. 13/864,179 Office Action dated Aug. 15, 2013.
[cited by applicant]
U.S. Appl. No. 14/063,884 Office Action dated Aug. 28, 2014.
[cited by applicant]
U.S. Appl. No. 14/063,884 Office Action dated Feb. 12, 2014.
[cited by applicant]
U.S. Appl. No. 14/067,841 Office Action dated Mar. 16, 2015.
[cited by applicant]
U.S. Appl. No. 14/194,566 Office Action dated May 15, 2014.
[cited by applicant]
U.S. Appl. No. 14/201,715 Office Action dated May 15, 2014.
[cited by applicant]
U.S. Appl. No. 14/201,726 Office Action dated May 16, 2014.
[cited by applicant]
U.S. Appl. No. 14/271,337 Office Action dated Jun. 12, 2014.
[cited by applicant]
U.S. Appl. No. 14/311,037 Office Action dated Sep. 5, 2014.
[cited by applicant]
U.S. Appl. No. 14/415,546 Office Action dated Apr. 28, 2016.
[cited by applicant]
U.S. Appl. No. 14/415,546 Office Action dated Oct. 7, 2016.
[cited by applicant]
U.S. Appl. No. 14/477,800 Office Action dated Dec. 15, 2014.
[cited by applicant]
U.S. Appl. No. 14/477,800 Office Action dated Feb. 2, 2015.
[cited by applicant]
U.S. Appl. No. 14/509,022 Office Action dated Jan. 15, 2015.
[cited by applicant]
U.S. Appl. No. 14/512,356 Office Action dated Feb. 5, 2015.
[cited by applicant]
U.S. Appl. No. 14/680,819 Office Action dated Dec. 3, 2015.
[cited by applicant]
U.S. Appl. No. 14/925,157 Office Action dated Mar. 22, 2016.
[cited by applicant]
U.S. Appl. No. 15/146,572 Office Action dated Jul. 11, 2019.
[cited by applicant]
U.S. Appl. No. 15/171,876 Office Action dated Oct. 12, 2016.
[cited by applicant]
U.S. Appl. No. 15/293,062 Office Action dated Mar. 22, 2017.
[cited by applicant]
U.S. Appl. No. 15/320,730 Office Action dated Oct. 4, 2017.
[cited by applicant]
U.S. Appl. No. 15/974,591 Office Action dated Jan. 2, 2020.
[cited by applicant]
U.S. Appl. No. 15/974,591 Office Action dated Mar. 21, 2019.
[cited by applicant]
U.S. Appl. No. 15/974,591 Office Action dated Sep. 5, 2018.
[cited by applicant]
U.S. Appl. No. 15/991,717 Office Action dated Jul. 9, 2019.
[cited by applicant]
U.S. Appl. No. 15/991,717 Office Action dated Nov. 2, 2018.
[cited by applicant]
U.S. Appl. No. 16/355,462 Office Action dated Aug. 18, 2021.
[cited by applicant]
U.S. Appl. No. 16/355,462 Office Action dated Jan. 21, 2021.
[cited by applicant]
U.S. Appl. No. 16/355,462 Office Action dated Sep. 3, 2020.
[cited by applicant]